These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21352502)

  • 1. A new generation of potent complement inhibitors of the Compstatin family.
    López de Victoria A; Gorham RD; Bellows-Peterson ML; Ling J; Lo DD; Floudas CA; Morikis D
    Chem Biol Drug Des; 2011 Jun; 77(6):431-40. PubMed ID: 21352502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles.
    Furlong ST; Dutta AS; Coath MM; Gormley JJ; Hubbs SJ; Lloyd D; Mauger RC; Strimpler AM; Sylvester MA; Scott CW; Edwards PD
    Immunopharmacology; 2000 Jul; 48(2):199-212. PubMed ID: 10936517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of structure-activity relations of complement inhibitor compstatin.
    Soulika AM; Morikis D; Sarrias MR; Roy M; Spruce LA; Sahu A; Lambris JD
    J Immunol; 2003 Aug; 171(4):1881-90. PubMed ID: 12902490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular dynamics in drug design: new generations of compstatin analogs.
    Tamamis P; López de Victoria A; Gorham RD; Bellows-Peterson ML; Pierou P; Floudas CA; Morikis D; Archontis G
    Chem Biol Drug Des; 2012 May; 79(5):703-18. PubMed ID: 22233517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin.
    Sahu A; Soulika AM; Morikis D; Spruce L; Moore WT; Lambris JD
    J Immunol; 2000 Sep; 165(5):2491-9. PubMed ID: 10946275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation.
    Nilsson B; Larsson R; Hong J; Elgue G; Ekdahl KN; Sahu A; Lambris JD
    Blood; 1998 Sep; 92(5):1661-7. PubMed ID: 9716594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of a modified mouse protein with ligand binding properties of its human analog by molecular dynamics simulations: the case of C3 inhibition by compstatin.
    Tamamis P; Pierou P; Mytidou C; Floudas CA; Morikis D; Archontis G
    Proteins; 2011 Nov; 79(11):3166-79. PubMed ID: 21989937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin.
    Magotti P; Ricklin D; Qu H; Wu YQ; Kaznessis YN; Lambris JD
    J Mol Recognit; 2009; 22(6):495-505. PubMed ID: 19658192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compstatin: a complement inhibitor on its way to clinical application.
    Ricklin D; Lambris JD
    Adv Exp Med Biol; 2008; 632():273-92. PubMed ID: 19025129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of compstatin family as therapeutic complement inhibitors.
    Huang Y
    Expert Opin Drug Discov; 2018 May; 13(5):435-444. PubMed ID: 29402126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3.
    Soulika AM; Holland MC; Sfyroera G; Sahu A; Lambris JD
    Mol Immunol; 2006 May; 43(12):2023-9. PubMed ID: 16472861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and activity of thioether-containing analogues of the complement inhibitor compstatin.
    Knerr PJ; Tzekou A; Ricklin D; Qu H; Chen H; van der Donk WA; Lambris JD
    ACS Chem Biol; 2011 Jul; 6(7):753-60. PubMed ID: 21520911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of the anti-C3 activity of compstatin using rational and combinatorial approaches.
    Morikis D; Soulika AM; Mallik B; Klepeis JL; Floudas CA; Lambris JD
    Biochem Soc Trans; 2004 Feb; 32(Pt 1):28-32. PubMed ID: 14748706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin.
    Katragadda M; Magotti P; Sfyroera G; Lambris JD
    J Med Chem; 2006 Jul; 49(15):4616-22. PubMed ID: 16854067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency.
    Qu H; Magotti P; Ricklin D; Wu EL; Kourtzelis I; Wu YQ; Kaznessis YN; Lambris JD
    Mol Immunol; 2011 Jan; 48(4):481-9. PubMed ID: 21067811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thermodynamic studies on the interaction of the third complement component and its inhibitor, compstatin.
    Katragadda M; Morikis D; Lambris JD
    J Biol Chem; 2004 Dec; 279(53):54987-95. PubMed ID: 15489226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The structural basis of compstatin activity examined by structure-function-based design of peptide analogs and NMR.
    Morikis D; Roy M; Sahu A; Troganis A; Jennings PA; Tsokos GC; Lambris JD
    J Biol Chem; 2002 Apr; 277(17):14942-53. PubMed ID: 11847226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational analysis of complement inhibitor compstatin using molecular dynamics.
    Devaurs D; Antunes DA; Kavraki LE
    J Mol Model; 2020 Aug; 26(9):231. PubMed ID: 32789582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition.
    Janssen BJ; Halff EF; Lambris JD; Gros P
    J Biol Chem; 2007 Oct; 282(40):29241-7. PubMed ID: 17684013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.
    Mastellos DC; Yancopoulou D; Kokkinos P; Huber-Lang M; Hajishengallis G; Biglarnia AR; Lupu F; Nilsson B; Risitano AM; Ricklin D; Lambris JD
    Eur J Clin Invest; 2015 Apr; 45(4):423-40. PubMed ID: 25678219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.